Latent Labs: AI-designed, ready-to-develop biologics

Using powerful AI models built by the minds behind AlphaFold2, Latent Labs engineers de novo drug-like, high-affinity biologics for challenging targets, aiming to overcome the problem of immunogenicity at the start and increase the chance of success in the clinic.

Emerging from stealth in February 2025, the London-based biotech has now built two AI platforms since its founding in 2023. Using “frontier” models, generative foundation models trained on public and proprietary data, the platforms create de novo macrocycles and antibodies for hard-to-drug targets. ...